ASSET OVERVIEW
A closer look at the opportunity.
Next-Generation HER2 ADC
Biparatopic design for enhanced binding, internalization, and bystander effect.
Proven Stability & Potency
Utilizes the same TOPO-1 inhibitor DXd payload as Enhertu, but with superior serum stability.
Strong Preclinical & Clinical Data
Demonstrates efficacy even in trastuzumab-insensitive tumors with lower free payload exposure vs. T-DXd.
Phase 3 Clinical Trials Ongoing Globally
2L+ HER2 low breast cancer, 2L+ HER2-positive breast cancer, Platinum-resistant ovarian cancer (PROC)
Expansive Development Pipeline
Targeting HER2-positive & HER2-low breast, gastric, ovarian, and other solid tumors.
Source: existing JEA asset materials. These descriptions include historical development plans and sponsor-reported data; contact JEA for current status and supporting materials.
← Back to all opportunities